J.M. Arbour LLC Acquires Shares of Incyte Corporation

Institutional investor adds to biotech firm's stock position

Apr. 17, 2026 at 8:38am

Got story updates? Submit your updates here. ›

An extreme close-up of complex pharmaceutical manufacturing equipment and machinery, conveying the technical sophistication and high stakes of the biotech industry without using any text or symbols.An institutional investor's increased stake in a leading biotech firm signals ongoing Wall Street interest in the company's innovative drug pipeline.Wilmington Today

J.M. Arbour LLC, an institutional investor, acquired a new position in shares of Incyte Corporation (NASDAQ:INCY) during the fourth quarter, according to a recent SEC filing. The fund purchased 8,488 shares of the biopharmaceutical company's stock, valued at approximately $838,000.

Why it matters

Incyte is a leading biotech firm focused on developing novel cancer and inflammation therapies. Institutional investors closely monitor the company's stock performance and ownership changes, as they can signal broader market sentiment and potential future growth.

The details

According to the 13F filing, J.M. Arbour LLC was not previously a shareholder of Incyte. The new position represents a small but meaningful stake in the company. Several other institutional investors also made changes to their Incyte holdings during the fourth quarter, including increases by Mirae Asset Global Investments and Parcion Private Wealth.

  • J.M. Arbour LLC acquired the new Incyte position during the fourth quarter of 2025.
  • The 13F filing disclosing the transaction was published on April 17, 2026.

The players

J.M. Arbour LLC

An institutional investment firm that acquired a new position in Incyte Corporation.

Incyte Corporation

A Wilmington, Delaware-based biopharmaceutical company focused on developing novel therapies in oncology and inflammation.

Got photos? Submit your photos here. ›

What’s next

Investors will continue to monitor Incyte's stock performance and any further changes in institutional ownership as the company progresses its drug development pipeline.

The takeaway

The acquisition of Incyte shares by J.M. Arbour LLC signals ongoing institutional interest in the biotech firm's potential, despite some recent stock price volatility. Incyte's focus on innovative therapies for cancer and inflammation makes it an attractive long-term investment for many funds.